Coherus Oncology, Inc. CHRS
0.37 USD -0.02 (-4.47%)
Regular-session close
0.37 0.00 +0.59%
After hours · Nov 20, 6:09 PM ET
0.3628 Day range 0.4084
0.3628 52-week range 2.62
- YTD
- -73.96%
- 1 year
- -66.38%
News
zacks.com Here's Why Coherus Oncology (CHRS) Is a Great 'Buy the Bottom' Stock Now Coherus Oncology (CHRS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement…
zacks.com Down 49.7% in 4 Weeks, Here's Why Coherus Oncology (CHRS) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Coherus Oncology (CHRS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers PepGen (NASDAQ:PEPG) stock rose 126.6% to $5.42 during Tuesday's regular session. The company's market cap stands at $165.5 million. The company's, Q3 earnings came out today. Nano X Imagingbenzinga.com Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $8 Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $10 to $8.
benzinga.com Coherus BioSciences Q3 2026 Earnings Call Transcript Coherus BioSciences (NASDAQ:CHRS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Coherus BioSciences Q3 Adj. EPS $(0.20) Beats $(0.22) Estimate, Sales $14.274M Miss $16.005M Estimate Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by 9.09 percent. This is a 39.39 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The company's market cap stands at $10.7 billion. The company's, Q3 earnings came out yesterday. Teladoc…benzinga.com HC Wainwright & Co. Assumes Coherus Oncology at Buy, Announces Price Target of $7 HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Coherus Oncology (NASDAQ:CHRS) with a Buy rating and announces Price Target of $7.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
